Stockwatch: Orchestrating investors in the dark
This article was originally published in Scrip
Executive Summary
The history of the biotechnology sector is punctuated by binary events. These are mostly clinical or regulatory developments that result in big share price moves. Until recently, an IPO acted like a binary event with big upward share price moves on the first day of trading. What most investors do not realize is that that IPOs can be the result of months or even years of careful orchestration in order to get the story presented to investors straight, even if it is highly spun.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.